Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.33% | 98.28% | 51.97% | 18.54% | 30.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.33% | 98.28% | 51.97% | 18.54% | 30.44% |
| Cost of Revenue | 150.87% | 106.51% | 18.59% | 0.34% | -2.87% |
| Gross Profit | 73.04% | 92.43% | 87.71% | 34.02% | 64.41% |
| SG&A Expenses | 45.35% | 98.43% | 64.47% | 46.97% | 9.89% |
| Depreciation & Amortization | -51.72% | -63.68% | -46.49% | -28.28% | -12.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.48% | 54.67% | 40.16% | 34.27% | 13.75% |
| Operating Income | -6.70% | -39.35% | -35.91% | -40.92% | -8.88% |
| Income Before Tax | 6.27% | -21.13% | -60.18% | -67.98% | -47.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.27% | -21.13% | -60.18% | -67.98% | -47.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.27% | -21.13% | -60.18% | -67.98% | -47.17% |
| EBIT | -6.70% | -39.35% | -35.91% | -40.92% | -8.88% |
| EBITDA | -17.70% | -63.69% | -63.42% | -59.51% | -9.72% |
| EPS Basic | 18.05% | -3.97% | -40.63% | -53.51% | -38.52% |
| Normalized Basic EPS | 6.99% | -19.51% | -26.42% | -36.62% | -22.37% |
| EPS Diluted | 18.05% | -3.97% | -40.63% | -53.51% | -38.52% |
| Normalized Diluted EPS | 6.99% | -19.51% | -26.42% | -36.62% | -22.37% |
| Average Basic Shares Outstanding | 15.04% | 17.78% | 15.68% | 10.65% | 6.01% |
| Average Diluted Shares Outstanding | 15.04% | 17.78% | 15.68% | 10.65% | 6.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |